ELISPOT – Page 2 – Communicable Diseases Research

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Article

Published on 2022-10-042022-11-15
Journal: PLoS Pathogens [Category] COVID19(2023년), SARS, 변종, 진단,

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers

Article

Published on 2022-10-032022-11-15
Journal: Pathogens and disease [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] assays B-cell baseline booster booster vaccines cellular Cellular immune response convalescent convalescent individual Coronavirus-2 determine ELISA ELISPOT ELISpot IFN-γ release assay first dose Health care worker health care workers hospital humoral humoral immune responses Humoral immunity IFN-γ IgG level IgG responses immune individual individuals interferon-γ janssen mounted mRNA mRNA vaccine natural immunity Netherlands occurred offer pandemic Pfizer postvaccination receiving recipient responses SARS-CoV-2 serological seronegative seropositive severe disease spike-specific cellular immunity Support T-cell T-cell Response vaccination Vaccine variants of concern vector vaccine Virus neutralization VNT waned
[DOI] 10.1093/femspd/ftac035 PMC 바로가기

Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19

Article

Published on 2022-10-012022-11-15
Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), SARS, 치료기술,

[키워드] absence Adaptive immune response anti-SARS-CoV-2 assays cellular cellular immunity correlated COVID-19 Culture detectable ELISPOT ELISpot assay enzyme-linked immunospot assay flow cytometry assay ICS Immunity IMPROVE intracellular cytokine intracellular cytokine staining intracellular cytokine staining assay magnitude median memory T memory T cells mononuclear cell nucleoprotein of SARS-CoV-2 Patient patients paucisymptomatic COVID-19. peptide pool performed Peripheral blood positive proportion response SARS-CoV-2 severe COVID-19 severe disease severe symptoms symptomatic T cell T cell response T cells the spike protein Vaccine-induced immunity
[DOI] 10.1002/iid3.617 PMC 바로가기

Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies

Article

Published on 2022-10-012022-11-15
Journal: Annals of Clinical and Translational Neurology [Category] COVID19(2023년), SARS, 진단,

[키워드] age Analysis antibody Antibody Response assays association cellular cellular response Cellular responses center COVID-19 infection COVID-19 vaccination ELISPOT evaluated examined groups hybrid IFNγ IL-2 immune response immune responses Immunity immunoassay immunologic response independent independent predictor Infection laboratory-confirmed Live virus microneutralization mRNA vaccines multivariate multivariate analyses New York no difference Patient post-vaccination response post-vaccine response receptor recruited SAR-CoV-2 SARS CoV-2 Sex significantly increased subset therapy vaccination Vaccine Vaccine-induced immunity were assessed
[DOI] 10.1002/acn3.51664 PMC 바로가기

One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents

코로나바이러스 질병 2019(COVID-19) 회복기의 1년 지속 세포 및 체액 면역

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, 치료법,

[키워드] antibodies antibody Antigen Asymptomatic cellular chemiluminescence immunoassay circulating cohort study conducted convalescent COVID-19 cytokine detectable disease disease onset disease severity ELISA ELISPOT enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot assay feature flow cytometry Humoral immunity IgG antibodies IgM IgM antibody immune immune memory Immunity Immunoglobulin individual intracellular cytokine staining membrane memory Microparticle Mild moderate N proteins neutralization neutralizing antibody nucleocapsid protein Nucleocapsid proteins positive SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2-specific antibodies SARS-CoV-2-specific IgG SARS-CoV-2-specific T-cell response severe disease specific antibodies specific IgG antibodies T cells T-cell T-cell responses the SARS-CoV-2 was tested were assessed
[DOI] 10.1093/cid/ciab884 PMC 바로가기 [Article Type] Article

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study

중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 특이적 T 세포 및 항체, 코로나바이러스 질병 2019(COVID-19) 보호: 전향적 연구

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus analyzed antibody Antibody Response Antibody responses CD4+ CD8+ T cell CD8+ T cells clinical comparable coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 correlated COVID-19 demonstrated ELISPOT enzyme enzyme-linked immunosorbent evaluated flow cytometry followed by fraction Fractions frequencies Frequency healthcare highest IFN-γ IgG immune immune response Immunoglobulin Immunoglobulin G immunoglobulin M individual Infection interferon gamma interleukin interleukin 2 Kaplan-Meier estimator membrane nucleocapsid pandemic positive Probability Prospective PROTECT protective effect question Registration respiratory response SARS-CoV-2 SARS-COV-2 infection Spike protein Spike proteins staining T cell T cells T-cell T-cell and antibody responses T-cell Response T-cell responses the SARS-CoV-2 virus virus-specific antibodies Virus-specific IgG were infected with infection
[DOI] 10.1093/cid/ciac278 PMC 바로가기 [Article Type] Article

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

ChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험

Clinical Trial

Published on 2022-08-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type
[DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial

Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

미경험 및 회복기 의료 종사자를 대상으로 백신 접종 후 SARS-CoV-2에 대한 T 세포 반응을 평가하기 위한 두 가지 T 세포 분석 비교

Comparative Study

Published on 2022-07-222022-09-11
Journal: Clinical and experimental immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법,

[키워드] acquisition antibody Antibody responses AZD1222 Blood BNT162b ChAdOx1 ChAdOx1 nCoV-19 characterized complex convalescent correlated strongly correlation dose ELISPOT ELISpot assay evaluate HCWs healthcare worker implication Infection less magnitude measure membrane moderate naïve Nucleocapsid proteins Oxford Panel pathway patient population peptides Pfizer Pfizer/BioNTech processing proportion protocol Region reported Reporting representing Research response responses SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein seasonal coronaviruses significantly lower Spike protein Spike-specific T-cell responses Standardization T cell T-cell T-cell assay T-cell Response T-cell responses vaccination Vaccine vaccinees virus
[DOI] 10.1093/cei/uxac042 PMC 바로가기 [Article Type] Comparative Study

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

MVA-MERS-S 백신으로 후기 3차 면역 후 MERS-CoV-스파이크 특이적 B 세포 및 항체의 지속성

Article

Published on 2022-07-192022-09-11
Journal: Cell Reports Medicine [Category] MERS, 임상, 진단,

[키워드] Administered antibody antibody isotypes B cell B cell response B cells binding boost booster booster vaccination caused coronavirus Coronavirus 2019 COVID-19 Cytometry ELISA ELISPOT ENhance enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot flow cytometry Frequency highlight homologous IgG IgG ELISpot IgG subclasses IgG1 immune immune persistence immune response immune responses Immunity immunization Immunoglobulin ImmunoSpot increase isotypes late booster vaccination long-term immunity longitudinal analysis memory B memory B cells MERS MERS coronavirus MERS-CoV MERS-S Middle East Middle East respiratory syndrome modified vaccinia virus MVA-MERS-S neutralization capacity neutralization test Neutralizing Neutralizing antibodies neutralizing antibody persistence Phase 1 phase 1 trial plaque-reduction neutralization test PRNT50 Protein respiratory Respiratory disease significantly Spike protein syndrome T and B cell responses T cell T cell responses Vaccination strategies Vaccine Viral Viral vector vaccine
[DOI] 10.1016/j.xcrm.2022.100685 PMC 바로가기 [Article Type] Article

Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

1년 동안 SARS-CoV-2-특이적 T 세포 사이토카인 생성 반응에 대한 종단 평가는 질병 중증도와 관련된 더 큰 면역과 함께 다중 사이토카인 증식 반응의 지속성을 보여줍니다

Article

Published on 2022-07-132022-09-11
Journal: Journal of Virology [Category] COVID19(2023년), SARS, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 all subjects assessment average CD4 CD8 Cell Cell-mediated immunity clone coronavirus Coronaviruses Critical cytokine cytokine response Cytokines declined demonstrated dominant ELISPOT ELISpot assay envelope enzyme-linked immunosorbent epitope Epitopes Ex vivo female Frequency gamma interferon granzyme B greater GzmB highlight IFN-γ IL-2 immune immune modeling. Immunity immunodominant immunodominant epitope immunodominant epitopes induce Infection interferon interleukin interleukin 2 kill longitudinal male median membrane nucleocapsid observation other coronaviruses peaked persistence post-symptom onset potent predicted produced producing proliferative PSO reduced regions response robust SARS-CoV-1 SARS-CoV-2 seasonal coronavirus seasonal coronaviruses severe acute respiratory syndrome Coronavirus severe disease structural protein structural proteins subject survivor T cell T cell immunity T cell memory T cell response T cell responses T cells target cells Vaccine viral infections Year
[DOI] 10.1128/jvi.00509-22 PMC 바로가기 [Article Type] Article